Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report emphasizes the significance of the ESMO conference, highlighting the achievements of Chinese pharmaceutical companies and suggesting to focus on catalysts such as policies, academic conferences, and business development in Q4 2025 [1][4] - The report indicates a potential market rebound due to increasing industry catalysts, including various academic conferences and favorable policies [4] - The report recommends continued attention to companies with promising clinical pipelines and their global commercialization potential [4][5] Valuation Summary - The report provides a detailed valuation overview of various companies, with all covered companies rated as "Buy" except for two rated as "Neutral" and one as "Sell" [3] - Notable target prices and current prices for selected companies include: - AstraZeneca: Target price 93.30, Current price 83.87 [3] - BeiGene: Target price 225.00, Current price 188.20 [3] - Innovent Biologics: Target price 48.00, Current price 36.42 [3] - I-Mab: Target price 105.00, Current price 86.10 [3] - China Biologic Products: Target price 9.10, Current price 7.43 [3] Market Performance - The Hang Seng Index rose by 2.3% and the Hang Seng Healthcare Index increased by 2.0% during the week of October 14-21, 2025, ranking fifth among twelve industry indices [4][7] - Sub-industry performance showed CXO leading with a 4.5% increase, followed by Internet medicine and biopharmaceuticals [4][7] Institutional Holdings - As of October 21, 2025, the proportion of domestic institutional holdings through Hong Kong Stock Connect decreased slightly to 22.1%, while foreign institutional holdings also saw a minor decline to 38.6% [34][38] - The report notes that both domestic and foreign investors are increasing their positions in innovative drug companies with clear pipeline values [4][38] Clinical Developments - The report highlights significant clinical trial results presented at the ESMO conference, including: - CanSino Biologics' promising data on its PD-1/VEGF inhibitor [5][6] - Rongchang Biopharmaceuticals' HER2 ADC showing significant survival benefits [5][6] - Kelun-Biotech's results indicating substantial improvements in progression-free survival [5][6] - The report suggests that these developments enhance the global competitiveness of the covered companies [5][6]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - There is a divergence between domestic and foreign capital in the pharmaceutical sector, with a focus on timing and selecting undervalued quality stocks in the innovative drug supply chain [1][4] - The report suggests that after a broad rally in innovative drugs, the importance of timing and stock selection has significantly increased, recommending gradual positioning during market corrections [4] Market Performance - The Hang Seng Index rose by 1.9% during the week of September 9-16, 2025, while the Hang Seng Healthcare Index fell by 3.0%, ranking 12th among 12 industry indices [4][8] - Sub-industry performance varied, with hospitals (+27.1%) and medical devices (+6.8%) showing gains, while biopharmaceuticals (-2.2%) and internet medicine (-3.5%) declined [4][8] Institutional Holdings - As of September 16, 2025, domestic capital's holding ratio through Hong Kong Stock Connect remained stable at 22.1%, while foreign capital's holding ratio decreased to 38.4% [33][38] - Domestic investors have been increasing their positions in leading and innovative drug companies, while foreign investors have shown a preference for CXO companies with better cost-performance ratios [4][38] Valuation Overview - The report provides a valuation summary for various companies, with target prices and ratings indicating a generally bullish outlook on innovative drug companies [3] - The average price-to-earnings ratio (P/E) for the pharmaceutical sector is noted, with specific segments like prescription drugs at 31.4 times and biopharmaceuticals at 14.2 times [17] Regulatory Developments - The National Medical Products Administration (NMPA) announced a fast-track review process for innovative drug clinical trial applications, aiming to streamline approvals for certain categories of drugs [7] - The report discusses the latest draft of the national centralized drug procurement rules, highlighting systematic optimizations in bidding mechanisms and quality assurance requirements [6][7]